상세 보기
Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis
- Kang, Y-K.;
- Qin, S.;
- Lee, K-W.;
- Oh, S. C.;
- Kim, I-H.;
- 외 10명
Citations
WEB OF SCIENCE
0- 제목
- Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis
- 저자
- Kang, Y-K.; Qin, S.; Lee, K-W.; Oh, S. C.; Kim, I-H.; Kim, J. G.; Li, Y.; Yan, Z.; Li, J.; Bai, L-Y.; Chan, C. P. K.; Yusuf, A.; Zahlten-Kuemeli, A.; Taylor, K.; Yamaguchi, K.
- 발행일
- 2023-11
- 유형
- Meeting Abstract
- 권
- 34
- 페이지
- S1525 ~ S1525
- 언어
- ENG
- 출판사
- ELSEVIER
- 발행국가
- 네덜란드
- ISSN
- E 1569-8041
P 0923-7534